INTRODUCTION
============

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) accounts for the largest proportion of mature T-cell and natural killer (NK)-cell neoplasms in the 2017 World Health Organization (WHO) classification.[@r1] We have found evidence that nodal cytotoxic molecule (CM)-positive PTCL-NOS \[(also called cytotoxic T-cell lymphoma (CTL)\] constitutes a unique category. This group encompasses a wide spectrum of presentations, ranging from indolent disease in a minority to an aggressive neoplasm in the majority; in 45-51% of CTL cases, the pathogenesis is closely associated with Epstein-Barr virus (EBV).[@r2]^,^[@r3] These biological properties are in clear contrast to those of nodal CM-negative T-cell neoplasms, which predominantly comprise PTCL-NOS, angioimmunoblastic T-cell lymphoma, and adult T-cell leukemia (ATLL, positive for human T-cell leukemia virus type 1)---although a small subset of patients (2%) may exhibit EBV-positive bystander lymphocytes.[@r2] This suggests that EBV is detected as the result of immunological deterioration in the tumor microenvironment, but that it plays little role in the pathogenesis of the latter neoplasm.

Among mature T/NK-cell tumors, the detection of EBV on tumor cells is essential for the diagnosis of nasal type NK/T-cell lymphoma (NKTL), aggressive NK-cell leukemia, or EBV^+^ T/NK-cell lymphoproliferative diseases of childhood---all of which exhibit CM expression and frequent extranodal involvement.[@r4] In most NKTL cases, the prototypic disease initially presents in the upper aerodigestive tract. This disease can also involve a wide variety of extranodal sites, including the skin and gastrointestinal tract, and may exhibit secondary lymph node lesions. Indeed, NKTL affecting middle-aged or elderly patients may feature de novo symptoms with clonal and rapid expansion of neoplastic EBV^+^ T/NK cells.[@r5]

Patients with nodal EBV^+^ CTL present with lymphadenopathy without nasopharyngeal involvement. However, this nodal lymphoma and NKTL share some biological properties, including CM expression and EBV positivity. We first elucidated the clinicopathological characteristics of nodal EBV^+^ CTL, which is characterized by diffuse monomorphic infiltration of large cells that often have a centroblastoid appearance, TCR expression, and gene rearrangement.[@r6]^-^[@r8] These findings indicate that nodal EBV^+^ CTL should be considered as a separate entity from NKTL; however, it remains controversial whether this disease is a variant of PTCL-NOS.

In this mini-review, we summarize the clinicopathological characteristics of nodal EBV^+^ CTL, with particular focus on its differences from NKTL, to further our understanding of this disease. We also discuss future perspectives regarding the treatment of nodal EBV^+^ disease. Nodal CTL without EBV-harboring tumor cells is beyond the scope of the present review, but it will be discussed in a future review, including the subject of indolent CD5^+^ cytotoxic nodal T/NK-cell lymphoproliferative disease affecting patients \<60 years old, which was newly identified by Yamashita *et al*.[@r3]

DEFINITION
==========

Nodal EBV^+^ CTL is defined as a primary nodal peripheral T-cell lymphoma characterized by a cytotoxic phenotype and EBV-harboring tumor cells ([Table 1](#t1){ref-type="table"}).[@r7] In all of the nodal EBV^+^ lymphoma cases, lymph node swelling was observed on initial presentation, or lymphadenopathy was the most prominent lesion at the time of diagnosis. The lymphoma cells are positive for at least one T-cell antigen (e.g., CD3, CD4, CD5, or CD8), in addition to constant expression of cytotoxic molecules and related antigens, including granzyme B, granzyme M, perforin, and/or T-cell intracellular antigen 1 (TIA1).[@r9] The category of nodal EBV^+^ CTL should exclude patients with upper aerodigestive tract involvement.

###### Clinicopathological features of nodal EBV^+^ CTL and NKTL

                      Nodal EBV^+^ CTL   NKTL
  ------------------- ------------------ -----------------
  Main lesion         Lymph node         Extranodal site
  Nasal involvement   --                 +/--
  CM expression       \+                 \+
  EBV association     \+                 \+
  CD8                 +/--               --/+
  CD56                --/+               +/--

EBV, Epstein-Barr virus; CTL, cytotoxic T-cell lymphoma; NKTL, NK/T-cell lymphoma of nasal type; CM, cytotoxic molecule

EPIDEMIOLOGY
============

Most nodal EBV^+^ CTL cases have been reported from East Asia, including Japan and Korea, which a geographical distribution similar to that of other EBV^+^ T/NK-cell neoplasms, i.e., NKTL and chronic active EBV infection (CAEBV) of the T- and NK-cell type.[@r4]^,^[@r6]^,^[@r7]^,^[@r10]^-^[@r16] Despite several reports on nodal EBV^+^ CTL,[@r2]^,^[@r6]^-^[@r8]^,^[@r10]^-^[@r14]^,^[@r17]^-^[@r20] its incidence remains to be clarified. Asano *et al*. found that the nodal EBV^+^ lymphoma accounted for 21% of nodal PTCL-NOS.[@r2] With a cut-off value of \> 25% EBER-positive neoplastic cells, EBV positivity of PTCL-NOS was reported to be 5-31%.[@r21]^,^[@r22] On the other hand, EBV was detected in 6% of PTCL-NOS with a cut-off value of \> 50% EBER-positive neoplastic cells.[@r21]

The clinicopathological features of nodal EBV^+^ CTL in previous studies (more than 10 cases) are summarized in [Table 2](#t2){ref-type="table"}. Nodal EBV^+^ CTL can develop across a wide range of ages, in infants to the elderly, but it predominantly affects middle-aged and elderly people, with a reported median age of 61-64 years.[@r3]^,^[@r6]^,^[@r10]^,^[@r14] Male predominance has been described, with a M:F ratio of 1.5-3.8:1.[@r3]^,^[@r6]^,^[@r7]^,^[@r10] Some cases may be associated with autoimmune diseases and immunosuppressive treatment.[@r7]

###### Summary of major reports\* on the clinicopathological features of nodal EBV^+^ CTL

  Author                                      Yamashita *et al*.[@r3]   Ng *et al*.[@r6]      Jeon *et al*.[@r10]   Kato *et al*.[@r7]                                 Kato *et al*.[@r8]
  ------------------------------------------- ------------------------- --------------------- --------------------- -------------------------------------------------- ----------------------
  Reference                                   Cancer Science. 2018      Haematologica. 2018   Hum Pathol. 2015      The American Journal of Surgical Pathology. 2015   Histopathology. 2012
  Cases (No.)                                 48                        19                    15                    39                                                 26
  Median age (years)                          62                        61                    64                    61                                                 62
  Sex (male/female)                           33/15                     15/4                  9/6                   26/13                                              15/11
  Clinical stage III/IV (n \[%\])             40/46 (86)                15/17 (88)            13/15 (87)            34/39 (87)                                         23/26 (88)
  IPI High-intermediate/High (n \[%\])        29/45 (64)                NA                    13/15 (87)            25/38 (66)                                         19/26 (73)
  Thrombocytopenia (n \[%\])                  22/40 (55)                NA                    8/15 (53)             21/34 (62)                                         11/22 (50)
  Extranodal involvement \>1 site (n \[%\])   7/47 (15)                 NA                    5/15 (29)             7/39 (18)                                          NA
  Extranodal sites                                                                                                                                                     
  BM (n \[%\])                                11/45 (24)                NA                    4/14 (29)             11/38 (29)                                         7/26 (27)
  Liver (n \[%\])                             15/46 (32)                NA                    9/15 (60)             14/39 (36)                                         9/26 (35)
  Skin and/or soft tissue (n \[%\])           1/46 (2)                  NA                    0/15 (0)              1/39 (3)                                           1/26 (4)
  GI tract (n \[%\])                          1/46 (2)                  NA                    1/14 (7)              1/39 (3)                                           1/26 (4)
  Median OS (months)                          8.0                       2.5                   3.5                   4.0                                                6.6
  Immunophenotype                                                                                                                                                      
  CD3 (n \[%\])                               46/48 (95)                NA                    15/15 (100)           37/39 (95)                                         24/26 (92)
  CD4 (n \[%\])                               9/47 (19)                 NA                    3/15 (20)             6/39 (15)                                          7/25 (28)
  CD5 (n \[%\])                               14/47 (29)                NA                    NA                    10/39 (26)                                         11/25 (44)
  CD8 (n \[%\])                               30/47 (63)                12/18 (67)            10/15 (67)            28/39 (72)                                         17/25 (68)
  CD56 (n \[%\])                              6/48 (12)                 4/18 (22)             1/15 (7)              6/39 (15)                                          0/26 (0)†
  TCRβ(n \[%\])                               18/41 (43)                9/19 (47)             9/14 (64)             18/39 (46)                                         11/24 (46)
  TCRγ and/or δ(n \[%\])                      5/41 (12)                 0/11 (0)              0/8 (0)               5/39 (13)                                          NA
  T-cell type‡(n \[%\])                       33/41 (80)                16/19 (84)            11/12 (92)            33/39 (85)                                         NA

EBV, Epstein-Barr virus; CTL, cytotoxic T-cell lymphoma; IPI, International Prognostic Index; BM, bone marrow; GI tract, gastrointestinal tract; OS, overall survival; TCR, T-cell receptor; NA, not available

\*Studies reporting more than 10 cases of nodal EBV^+^ CTL were summarized.

†CD56^+^ nodal EBV^+^ CTL cases were excluded in the series (Histopathology. 2012;61:186-199).

‡Patients with T-cell type had positive TCR protein expression and/or TCRγ gene rearrangement

CLINICAL FEATURES AND PROGNOSIS
===============================

In most cases of nodal EBV^+^ CTL, the initial presentation involves lymphadenopathy with aggressive clinical features, including high frequencies of advanced clinical-stage disease (Ann Arbor III-IV) (86-88%), B symptoms (72-80%), high or high/intermediate IPI (64-87%), and thrombocytopenia (53-62%).[@r3]^,^[@r6]^,^[@r7]^,^[@r10] Some cases exhibit hepatic involvement (32-60%) or bone marrow involvement (24-29%). Other less commonly involved extranodal organs in our previous series[@r3] of 48 patients with the nodal EBV^+^ lymphoma were the lungs, peripheral blood, skin and/or soft tissue, gastrointestinal tract, bone, kidney, and adrenal gland (unpublished data). A minority of patients have two or more extranodal lesions (15-29%); this frequency is lower than that in NKTL (30-59%).[@r3]^,^[@r7]^,^[@r10]^,^[@r23] The median overall survival time of nodal EBV^+^ disease (2.5-8.0 months) is significantly poorer than that of NKTL (26-50 months)[@r3]^,^[@r6]^,^[@r7]^,^[@r10]^,^[@r14]^,^[@r23]^,^[@r24] or PTCL-NOS (16-20 months).[@r2]^,^[@r3]^,^[@r7]^,^[@r25]^,^[@r26]

MORPHOLOGY
==========

All cases of nodal EBV^+^ CTL present with high-grade morphology. In addition, we found that half of the cases had a centroblastoid appearance ([Fig. 1A](#f1){ref-type="fig"}), which was originally documented by Kagami *et al*., emphasizing the challenging differential diagnosis from diffuse large B-cell lymphoma in terms of morphology.[@r27] This unique cytopathological finding is reported in only approximately 15% of extranasal NKTL cases.[@r3]^,^[@r7] Moreover, the centroblastoid appearance is inconsistent with the pleomorphic and elongated nuclei found in prototypic nasal-type tumors ([Fig. 1B](#f1){ref-type="fig"}). Necrosis is more common in extranasal NKTL than in nodal disease.[@r7]

![Histopathological features of nodal EBV^+^ cytotoxic T-cell lymphoma (CTL). (*A*) Nodal EBV^+^ CTL is characterized by a centroblastoid appearance, morphologically resembling diffuse large B-cell lymphoma. (*B*) In contrast, nasal-type NK/T-cell lymphoma is characterized by pleomorphic and elongated nuclei. (*C* and *D*) In nodal EBV^+^ CTL, the tumor cells are positive for granzyme B (*C*) and CD8 (*D*). (*E*) EBV is detected by in-situ hybridization.](jslrt-60-30-g001){#f1}

IMMUNOPHENOTYPE
===============

According to the definition, all cases of nodal EBV^+^ CTL are positive for EBER *in-situ* hybridization and CMs ([Fig. 1C, E](#f1){ref-type="fig"}). Jeon *et al*. reported that the percentage of EBER positivity ranged from 40-80% in each case.[@r10] Accordingly, our unpublished data included positivity ranging from 50-90%. Of note, nodal EBV^+^ CTL is characterized by a CD8^+^ and CD56^−^ phenotype, and most cases demonstrate positivity for CD3. CD8 positivity is detected in the majority of the cases (63-72%, [Fig. 1D](#f1){ref-type="fig"}), whereas positive CD56 expression is infrequent (12-22%).[@r3]^,^[@r6]^,^[@r7]^,^[@r10]^,^[@r13] This phenotype is in clear contrast to the CD56^+^ and CD8^−^ phenotype of NKTL.[@r6]^,^[@r23]^,^[@r28]^-^[@r30] These phenotypic differences were also confirmed in the comparison between nodal EBV^+^ CTL and extranasal NKTL with secondary lymph node involvement.[@r8] A minority of nodal EBV^+^ lymphoma cases is positive for CD4 (15-20%) and CD5 (26-29%), having lower frequencies than in PTCL-NOS.[@r2]^,^[@r3]^,^[@r7]^,^[@r8]^,^[@r10] Positive CD30 expression has been reported in 37% of cases of nodal EBV^+^ disease (cut-off value \> 30%).[@r3] Positivity for surface CD3 in nodal EBV^+^ CTL has not been reported in the English literature.

Recently, increasing attention has been paid to the relationship between the T-cell receptor (TCR) phenotype and biological properties among mature T/NK-cell neoplasms.[@r29]^,^[@r31]^,^[@r32] T lymphocytes comprise two distinct lineages that perform non-overlapping roles in immune responses---distinguished by the expression of either αβ or γδ TCR complexes. In terms of localization, αβ T cells are primarily found in secondary lymphoid organs such as lymph nodes and tonsils.[@r33]^,^[@r34] In contrast, γδ T cells account for 2-4% of the T cells within lymph nodes, and up to 50% of the T cells at mucosal sites, particularly in the intestines and skin.[@r34]^-^[@r40] Based on TCRβ positivity, αβ T cells have been detected in 43-64% of nodal EBV^+^ CTL.[@r3]^,^[@r7]^,^[@r10] On the other hand, based on TCRγ and/or δ positivity, γδ T cells are found in 0-13% of nodal EBV^+^ disease.[@r3]^,^[@r7]^,^[@r10] Notably, in our previous report, all five patients with TCRγδ^+^ nodal EBV^+^ lymphoma exhibited a highly aggressive clinical course and died within 3 months, with a median survival of 2 months.[@r7] Furthermore, all three patients with available clinical information had a medical history of autoimmune disease, and two had undergone previous treatment using immunosuppressive agents.[@r7] Further studies are needed to clarify which is more important for lymphomagenesis of TCRγδ^+^ nodal EBV^+^ disease: a history of autoimmune disease or prior use of immunosuppressive agents.

Following advancements in immuno-oncology, increasing numbers of reports have highlighted the neoplastic programmed cell-death ligand 1 (PD-L1) expression on tumor cells in lymphoma entities, including NKTL. We recently reported a small subset of nodal EBV^+^ CTL (8 of 22 cases; 9%) with neoplastic PD-L1 expression detected by staining with anti-PD-L1 antibody, clone SP142.[@r3] These findings will be discussed in a separate manuscript currently in preparation by Yamashita *et al*.

CELL OF ORIGIN
==============

Most nodal EBV^+^ CTL cases (80-92%) are positive for TCR protein expression and/or *TCRγ* gene rearrangement detected by PCR, i.e., the T-cell type.[@r3]^,^[@r6]^,^[@r7]^,^[@r10] Based on our unpublished data, *TCRγ* gene rearrangement was found in 71% of the nodal cases. The *TCRγ* gene rearrangement frequency in nodal EBV^+^ disease is consistent with findings in other peripheral T-cell lymphomas, including PTCL-NOS, angioimmunoblastic T-cell lymphoma, and adult T-cell leukemia/lymphoma (71-84%).[@r3]^,^[@r41] On the other hand, NKTL generally lacks TCR protein expression and *TCR* gene rearrangement, with detection rates ranging from 0-14% by immunohistochemistry[@r7]^,^[@r19]^,^[@r29] and 9.5-40% by PCR or Southern blot analysis.[@r6]^,^[@r7]^,^[@r19]^,^[@r23]^,^[@r28]^,^[@r30] These findings additionally support nodal EBV^+^ CTL being distinct from NKTL.[@r4]

Recently, Ng *et al*. compared the clinicopathological features in T-cell type cases of nodal EBV^+^ CTL with those in NKTL to clarify whether the differences between nodal EBV^+^ CTL and NKTL were simply related to lineage.[@r6] They revealed that older age, CD8 expression, and poor outcome remained significantly associated with T-cell type cases of nodal EBV^+^ lymphoma compared with those of NKTL, confirming that nodal EBV^+^ CTL is distinct from NKTL regardless of the cell of origin.

RELATIONSHIP WITH EBV^+^ T/NK-CELL LYMPHOPROLIFERATIVE DISEASES OF CHILDHOOD
============================================================================

The clinical course of patients with nodal EBV^+^ CTL may include a prodromal phase of chronic active EBV infection (CAEBV). Indeed, in our previous series of 48 patients with nodal EBV^+^ CTL, 5 patients had a history of EBV^+^ T/NK-cell lymphoproliferative diseases of childhood (unpublished data).[@r3] Among these 5 patients, the ages at overt EBV^+^ lymphoma diagnosis were 3, 29, 40, 50, and 55 years. This suggests that nodal EBV^+^ CTL is related to CAEBV of T- and NK-cell types, systemic form or systemic EBV^+^ T-cell lymphoma of childhood. We previously reported a case of EBV^+^ T/NK-cell lymphoma that preceded the clinical presentation of CAEBV.[@r42] The results of *TCR*γ gene rearrangement analysis suggested that all detectable lymphoma/lymphoproliferative disease (LPD) affecting this patient originated from the same clone throughout the long-term process of EBV^+^ neoplasia over 18 years, eventually leading to death at 48 years of age. These findings suggest a close relationship between EBV^+^ T/NK-cell lymphoma and CAEBV in terms of developmental background, especially in younger patients.

Takahashi *et al*. reported that patients with monoclonal CAEBV-associated NK-cell LPD exhibit clinicopathological features similar to those in younger patients (≤50 years of age) with NKTL and aggressive NK-cell leukemia/lymphoma, and 25% of these patients exhibited hypersensitivity to mosquito bites.[@r43] Recently, Kawamoto *et al*. reported that patients with adult-onset CAEBV less frequently exhibit hypersensitivity to mosquito bites and hydroa vacciniforme, but more frequently had accompanying hemophagocytic syndrome and exhibited a poorer outcome than pediatric-onset patients (age of onset estimated at \<15 years).[@r44] This constellation of findings suggests differences in pathogenesis between young-onset and elderly-onset nodal EBV^+^ CTL. The pathogenesis of elderly-onset nodal EBV^+^ CTL may be associated with EBV activation in T cells due to immune senescence with age, even if this is much less frequent than that in B cells.

TREATMENT
=========

There is no clear standard treatment for nodal EBV^+^ CTL. The prognosis of nodal EBV^+^ disease is markedly poor when treated using the CHOP regimen.[@r10] In our previous series of the nodal lymphoma, 71% of patients were treated using anthracycline-containing combined chemotherapy;[@r3] however, chemotherapeutic regimens with anthracycline did not improve overall survival (data not shown). Recent reports suggest that l-asparaginase-based regimens, including SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide), are effective against advanced-stage NKTL.[@r45]^-^[@r49] Although no report describes the treatment of nodal EBV^+^ CTL using the SMILE regimen, such treatment may be superior to the CHOP regimen for nodal EBV^+^ CTL patients. Further investigations are needed to examine the effects of SMILE therapy on nodal EBV^+^ disease.

Programmed death 1 (PD-1)/PD-L1 pathway inhibitors have recently demonstrated great promise in treating various malignancies, including Hodgkin and non-Hodgkin lymphoma.[@r50]^-^[@r52] Previous studies reported PD-L1 expression in NKTL, and anti-PD-1 immunotherapy is reportedly effective in patients with NKTL.[@r53]^-^[@r55] Ng *et al*. detected upregulation of PD-L1 mRNA in nodal EBV^+^ CTL compared with in NKTL.[@r6] This PD-L1 upregulation in the nodal EBV^+^ disease may have potential therapeutic implications for anti-PD-1 treatment.

CONCLUSION
==========

In this review, we mainly focused on summarizing the clinicopathological characteristics of nodal EBV^+^ CTL---a systemic disease with an aggressive clinical course and CD8^+^/CD56^−^ phenotype that is distinct from NKTL and PTCL-NOS. Most cases of nodal EBV^+^ CTL exhibit a T-cell origin, supporting the clinicopathological uniqueness of this nodal disease. Of note, in our series of Japanese patients with nodal CTLs, EBV presence on tumor cells had no prognostic impact.[@r3] However, EBV detection may be a useful predictive factor for the delineation of therapeutic targets in immuno-oncology-based clinical trials, as the viral agents may be linked with PD-L1 upregulation.[@r56] Overall, nodal EBV^+^ CTL should be regarded as an aggressive disease that currently presents challenges regarding clinical management and therapeutic approaches. Further investigations are needed to establish appropriate therapeutic strategies against nodal EBV^+^ CTL.
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